Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Health Aff (Millwood). 2012 Nov;31(11):2518-27. doi: 10.1377/hlthaff.2012.0104.
In response to the 2009 H1N1 pandemic and subsequent vaccination program, the Department of Health and Human Services and collaborators developed the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) Program as a demonstration project to detect rare adverse events rapidly. The program monitored three million people who had received the H1N1 vaccine by linking data from large private health plans and from public immunization registries that had originally not been designed to share data, and on a larger scale than had been previously attempted. The program generated safety data in two weeks rather than three to six monty 10ths-the standard time frame achievable using health plan data. PRISM substantially contributed to the understanding of the safety of H1N1 vaccines. Its use in the case of H1N1 highlights the necessity of proactive planning, scalable infrastructure, and public-private partnerships in tracking adverse events after vaccination in epidemics. It also illustrates how data could be integrated to produce policy-relevant information for other medical products.
针对 2009 年的 H1N1 大流行和随后的疫苗接种计划,美国卫生与公众服务部及其合作者开发了上市后快速免疫安全性监测(PRISM)计划,作为一个示范项目,以快速发现罕见的不良事件。该计划通过将来自大型私人健康计划的数据与最初并非为共享数据而设计的公共免疫登记处的数据进行链接,监测了 300 万人接种了 H1N1 疫苗,其规模比以前尝试的要大。该计划在两周内而不是标准的三到六个月生成安全性数据,使用健康计划数据可以达到这个时间框架。PRISM 极大地促进了对 H1N1 疫苗安全性的理解。在 H1N1 案例中的应用突出了在流行病中跟踪疫苗接种后不良事件时进行积极主动的规划、可扩展的基础设施和公私合作伙伴关系的必要性。它还说明了如何整合数据以针对其他医疗产品生成与政策相关的信息。